drug_type
RELEVANT_DRUG
intervention_type
Antibody-drug conjugate (HER2-directed)
drug_description
HER2-directed antibody-drug conjugate linking trastuzumab to DM1 (maytansinoid) microtubule inhibitor.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ado-Trastuzumab Emtansine
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-directed antibody-drug conjugate: trastuzumab binds ERBB2/HER2 and is internalized; lysosomal processing of the non-cleavable MCC linker releases active Lys-MCC-DM1, a maytansinoid microtubule inhibitor that causes mitotic arrest and apoptosis. Trastuzumab also inhibits HER2 signaling and can mediate ADCC.
drug_name
Ado-trastuzumab emtansine (T-DM1)
nct_id_drug_ref
NCT06439693